Polymorphisms of human cytochrome P450 2C9 and the functional relevance

Toxicology

Volumn 278, Issue 2, 2010, Pages 165-188

  Zhou, Shu Feng ^a   Zhou, Zhi Wei ^a   Huang, Min ^b  

^a RMIT UNIVERSITY   (Australia)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adverse effect; Biomarker; Clearance; CYP2C9; Enzyme activity; Ethnic; SNP

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIVITAMIN K; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; DICLOFENAC; DIURETIC AGENT; FLURBIPROFEN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LORNOXICAM; LOSARTAN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PIROXICAM; SULFONYLUREA DERIVATIVE; SUPROFEN; TENOXICAM; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ALLELE; ARTICLE; CAUCASIAN; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME SPECIFICITY; EPILEPSY; ETHNICITY; GENE MUTATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAIN; PHARMACOGENETICS; PREDICTION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH HEMORRHAGE; STROKE; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 78149470864     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.08.013     Document Type: Article

References (393)

1. Adithan C., Gerard N., Vasu S., Balakrishnan R., Shashindran C.H., Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur. J. Clin. Pharmacol. 2003, 59:707-709.
2. Aithal G.P., Day C.P., Leathart J.B., Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000, 10:511-518.
3. Akutsu T., Kobayashi K., Sakurada K., Ikegaya H., Furihata T., Chiba K. Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation. Drug Metab. Dispos. 2007, 35:72-78.
4. Albrecht W., Unger A., Nussler A.K., Laufer S. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab. Dispos. 2008, 36:894-903.
5. Allabi A.C., Gala J.L., Desager J.P., Heusterspreute M., Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. 2003, 56:653-657.
6. Allabi A.C., Gala J.L., Horsmans Y., Babaoglu M.O., Bozkurt A., Heusterspreute M., Yasar U. Functional impact of CYP2C9 5, CYP2C9 6, CYP2C9 8, and CYP2C9 11 in vivo among black Africans. Clin. Pharmacol. Ther. 2004, 76:113-118.
7. Allabi A.C., Gala J.L., Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genom. 2005, 15:779-786.
8. Andersson S.H., Lindgren A., Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Metab. Dispos. 1998, 26:528-535.
9. Aynacioglu A.S., Brockmoller J., Bauer S., Sachse C., Guzelbey P., Ongen Z., Nacak M., Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 1999, 48:409-415.
10. Babaoglu M.O., Yasar U., Sandberg M., Eliasson E., Dahl M.L., Kayaalp S.O., Bozkurt A. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur. J. Clin. Pharmacol. 2004, 60:337-342.
11. Badian M., Korn A., Lehr K.H., Malerczyk V., Waldhausl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol. Drug Interact. 1994, 11:331-339.
12. Bae J.W., Kim H.K., Kim J.H., Yang S.I., Kim M.J., Jang C.G., Park Y.S., Lee S.Y. Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 2005, 60:418-422.
13. Bae J.W., Kim J.H., Choi C.I., Kim M.J., Kim H.J., Byun S.A., Chang Y.S., Jang C.G., Park Y.S., Lee S.Y. Effect of CYP2C9 3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch. Pharm. Res. 2009, 32:269-273.
14. Bagshaw S.M., Delaney A., Haase M., Ghali W.A., Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit. Care Resusc. 2007, 9:60-68.
15. Bajpai M., Roskos L.K., Shen D.D., Levy R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 1996, 24:1401-1403.
16. Balant L., Fabre J., Zahnd G.R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur. J. Clin. Pharmacol. 1975, 8:63-69.
17. Ball S.E., Forrester L.M., Wolf C.R., Back D.J. Differences in the cytochrome P450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Relative activities of rat and human liver enzymes. Biochem. J. 1990, 267:221-226.
18. Barnhart J.W. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol. Appl. Pharmacol. 1980, 55:43-48.
19. Becquemont L., Mouajjah S., Escaffre O., Beaune P., Funck-Brentano C., Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab. Dispos. 1999, 27:1068-1073.
20. Benetton S.A., Borges V.M., Chang T.K., McErlane K.M. Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica 2004, 34:335-344.
21. Blaisdell J., Jorge-Nebert L.F., Coulter S., Ferguson S.S., Lee S.J., Chanas B., Xi T., Mohrenweiser H., Ghanayem B., Goldstein J.A. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004, 14:527-537.
22. Boberg M., Angerbauer R., Fey P., Kanhai W.K., Karl W., Kern A., Ploschke J., Radtke M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab. Dispos. 1997, 25:321-331.
23. Bohets H., Lavrijsen K., Hendrickx J., van Houdt J., van Genechten V., Verboven P., Meuldermans W., Heykants J. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br. J. Pharmacol. 2000, 129:1655-1667.
24. Bondesson U., Hartvig P., Danielsson B. Quantitative determination of the urinary excretion of ketobemidone and four of its metabolites after intravenous and oral administration in man. Drug Metab. Dispos. 1981, 9:376-380.
25. Bonnabry P., Leemann T., Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur. J. Clin. Pharmacol. 1996, 49:305-308.
26. Bort R., Ponsoda X., Carrasco E., Gomez-Lechon M.J., Castell J.V. Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab. Dispos. 1996, 24:969-975.
27. Bourrie M., Meunier V., Berger Y., Fabre G. Role of cytochrome P450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. 1999, 27:288-296.
28. Bovill E.G., Fung M., Cushman M. Vitamin K and oral anticoagulation: thought for food. Am. J. Med. 2004, 116:711-713.
29. Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest C.S., Lachno D.R., Salazar D., Winters K.J. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 2007, 5:2429-2436.
30. Bravo-Villalta H.V., Yamamoto K., Nakamura K., Baya A., Okada Y., Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol. 2005, 61:179-184.
31. Brenner S.S., Herrlinger C., Dilger K., Murdter T.E., Hofmann U., Marx C., Klotz U. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet. 2003, 42:283-292.
32. Burian M., Grosch S., Tegeder I., Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br. J. Clin. Pharmacol. 2002, 54:518-521.
33. Busse D., Cosme J., Beaune P., Kroemer H.K., Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol. 1995, 353:116-121.
34. Bussey H.I., Wittkowsky A.K., Hylek E.M., Walker M.B. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 2008, 28:141-143.
35. Caraco Y., Muszkat M., Wood A.J. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 2001, 11:587-596.
36. 1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 1993, 265:826-834.
37. Chando T.J., Everett D.W., Kahle A.D., Starrett A.M., Vachharajani N., Shyu W.C., Kripalani K.J., Barbhaiya R.H. Biotransformation of irbesartan in man. Drug Metab. Dispos. 1998, 26:408-417.
38. Chauret N., Yergey J.A., Brideau C., Friesen R.W., Mancini J., Riendeau D., Silva J., Styhler A., Trimble L.A., Nicoll-Griffith D.A. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg. Med. Chem. Lett. 2001, 11:1059-1062.
39. Chavez M.L., DeKorte C.J. Valdecoxib: a review. Clin. Ther. 2003, 25:817-851.
40. Chesne C., Guyomard C., Guillouzo A., Schmid J., Ludwig E., Sauter T. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998, 28:1-13.
41. 4 receptor antagonist, in humans. Drug Metab. Dispos. 1997, 25:1022-1031.
42. Choi M.H., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab. Dispos. 2005, 33:714-718.
43. Christensen M.L., Meibohm B., Capparelli E.V., Velasquez-Mieyer P., Burghen G.A., Tamborlane W.V. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with Type 2 diabetes. J. Clin. Pharmacol. 2005, 45:1137-1144.
44. Clarke T.A., Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 2003, 31:53-59.
45. Cotreau-Bibbo M.M., von Moltke L.L., Greenblatt D.J. Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. J. Pharm. Sci. 1996, 85:1180-1185.
46. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 2000, 28:772-780.
47. Crespi C.L., Miller V.P. The R144C change in the CYP2C9 2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997, 7:203-210.
48. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., Gillam E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 2002, 30:869-874.
49. 4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 1995, 23:406-414.
50. Dain J.G., Fu E., Gorski J., Nicoletti J., Scallen T.J. Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 1993, 21:567-572.
51. Dalvie D.K., O'Connell T.N. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab. Dispos. 2004, 32:49-57.
52. Dang M.T., Hambleton J., Kayser S.R. The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother. 2005, 39:1008-1012.
53. 1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab. Dispos. 2000, 28:79-88.
54. Davies N.M. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin. Pharmacokinet. 1995, 28:100-114.
55. Davies N.M., McLachlan A.J., Day R.O., Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase-2 inhibitor. Clin. Pharmacokinet. 2000, 38:225-242.
56. de Groot M.J., Alex A.A., Jones B.C. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem. 2002, 45:1983-1993.
57. Decker C.J., Laitinen L.M., Bridson G.W., Raybuck S.A., Tung R.D., Chaturvedi P.R. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 1998, 87:803-807.
58. Dickmann L.J., Rettie A.E., Kneller M.B., Kim R.B., Wood A.J., Stein C.M., Wilkinson G.R., Schwarz U.I. Identification and functional characterization of a new CYP2C9 variant (CYP2C9 5) expressed among African Americans. Mol. Pharmacol. 2001, 60:382-387.
59. Dingemanse J., van Giersbergen P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 2004, 43:1089-1115.
60. Dorado P., Berecz R., Norberto M.J., Yasar U., Dahl M.L.A.L.L. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 2003, 59:221-225.
61. Dorado P., Cavaco I., Caceres M.C., Piedade R., Ribeiro V., Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur. J. Clin. Pharmacol. 2008, 64:967-970.
62. Dunn C.J., Fitton A., Brogden R.N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995, 49:121-142.
63. Eagling V.A., Howe J.L., Barry M.J., Back D.J. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem. Pharmacol. 1994, 48:267-276.
64. Ebert B., Thorkildsen C., Andersen S., Christrup L.L., Hjeds H. Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochem. Pharmacol. 1998, 56:553-559.
65. Elliot D.J., Suharjono, Lewis B.C., Gillam E.M., Birkett D.J., Gross A.S., Miners J.O. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br. J. Clin. Pharmacol. 2007, 64:450-457.
66. Engel G., Hofmann U., Heidemann H., Cosme J., Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 1996, 59:613-623.
67. Erickson D.A., Mather G., Trager W.F., Levy R.H., Keirns J.J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450. Drug Metab. Dispos. 1999, 27:1488-1495.
68. Evans D.C., O'Connor D., Lake B.G., Evers R., Allen C., Hargreaves R. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos. 2003, 31:861-869.
69. Facciola G., Hidestrand M., von Bahr C., Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 2001, 56:881-888.
70. Firkusny L., Kroemer H.K., Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem. Pharmacol. 1995, 49:1777-1784.
71. Fischer T.L., Pieper J.A., Graff D.W., Rodgers J.E., Fischer J.D., Parnell K.J., Goldstein J.A., Greenwood R., Patterson J.H. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. 2002, 72:238-246.
72. Fischer V., Vickers A.E., Heitz F., Mahadevan S., Baldeck J.P., Minery P., Tynes R. The polymorphic cytochrome P4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab. Dispos. 1994, 22:269-274.
73. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.P., Robinson W.T. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos. 1999, 27:410-416.
74. Flockhart D.A., O'Kane D., Williams M.S., Watson M.S., Flockhart D.A., Gage B., Gandolfi R., King R., Lyon E., Nussbaum R., O'Kane D., Schulman K., Veenstra D., Williams M.S., Watson M.S. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 2008, 10:139-150.
75. Flores-Runk P., Raasch R.H. Ticlopidine and antiplatelet therapy. Ann. Pharmacother. 1993, 27:1090-1098.
76. Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999, 20:480-490.
77. Foster D.J., Somogyi A.A., Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 1999, 47:403-412.
78. Furuta S., Akagawa N., Kamada E., Hiyama A., Kawabata Y., Kowata N., Inaba A., Matthews A., Hall M., Kurimoto T. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br. J. Clin. Pharmacol. 2002, 54:295-303.
79. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., Idle J.R. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995, 5:389-392.
80. Gaedigk A., Casley W.L., Tyndale R.F., Sellers E.M., Jurima-Romet M., Leeder J.S. Cytochrome P450 2C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can. J. Physiol. Pharmacol. 2001, 79:841-847.
81. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 2004, 91:87-94.
82. Gage B.F., Eby C., Johnson J.A., Deych E., Rieder M.J., Ridker P.M., Milligan P.E., Grice G., Lenzini P., Rettie A.E., Aquilante C.L., Grosso L., Marsh S., Langaee T., Farnett L.E., Voora D., Veenstra D.L., Glynn R.J., Barrett A., McLeod H.L. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 2008, 84:326-331.
83. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmoller J., Frotschl R., Kopke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003, 59:303-312.
84. Garcia-Martin E., Martinez C., Ladero J.M., Gamito F.J., Agundez J.A. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. 2001, 57:47-49.
85. Garcia-Martin E., Martinez C., Tabares B., Frias J., Agundez J.A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 2004, 76:119-127.
86. Gardner I., Wakazono H., Bergin P., de Waziers I., Beaune P., Kenna J.G., Caldwell J. Cytochrome P450 mediated bioactivation of methyleugenol to 1'-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes. Carcinogenesis 1997, 18:1775-1783.
87. Gentile D.M., Verhoeven C.H., Shimada T., Back D.J. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J. Pharmacol. Exp. Ther. 1998, 287:975-982.
88. Gerber J.G., Rhodes R.J., Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004, 16:36-44.
89. Ghosal A., Ramanathan R., Yuan Y., Hapangama N., Chowdhury S.K., Kishnani N.S., Alton K.B. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab. Dispos. 2007, 35:2186-2195.
90. Giancarlo G.M., Venkatakrishnan K., Granda B.W., von Moltke L.L., Greenblatt D.J. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 2001, 57:31-36.
91. Gilissen R.A., Ferrari L., Barnaby R.J., Kajbaf M. Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in vitro-in vivo correlations. Xenobiotica 2000, 30:843-856.
92. Goldberg R., Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996, 62:1559-1564.
93. Goldstein J.A., Blaisdell J.A., Limdi N.A. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy. Blood Cells Mol. Dis. 2009, 42:155-158.
94. Goodstadt L., Ponting C.P. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem. Sci. 2004, 29:289-292.
95. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 1992, 267:83-90.
96. Grace J.M., Skanchy D.J., Aguilar A.J. Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica 1999, 29:703-717.
97. Greene M.F. Oral hypoglycemic drugs for gestational diabetes. N. Engl. J. Med. 2000, 343:1178-1179.
98. Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., Hassan M., Dahl M.L. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol. 2003, 59:103-109.
99. Gschwind H.P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M., Pokorny R., Seiberling M., Ben-Am M., Peng B., Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 2005, 33:1503-1512.
100. Guitton J., Buronfosse T., Desage M., Flinois J.P., Perdrix J.P., Brazier J.L., Beaune P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth. 1998, 80:788-795.
101. Guo Y., Wang Y., Si D., Fawcett P.J., Zhong D., Zhou H. Catalytic activities of human cytochrome P450 2C9 1, 2C9 3 and 2C9 13. Xenobiotica 2005, 35:853-861.
102. Guo Y., Zhang Y., Wang Y., Chen X., Si D., Zhong D., Fawcett J.P., Zhou H. Role of CYP2C9 and its variants (CYP2C9 3 and CYP2C9 13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos. 2005, 33:749-753.
103. Hadama A., Ieiri I., Morita T., Kimura M., Urae A., Irie S., Kaneda T., Mamiya K., Tashiro N., Higuchi S., Otsubo K. p-Hydroxylation of phenobarbital: relationship to S-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther. Drug Monit. 2001, 23:115-118.
104. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 1996, 333:447-458.
105. Hall S.D., Hamman M.A., Rettie A.E., Wienkers L.C., Trager W.F., Vandenbranden M., Wrighton S.A. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 1994, 22:975-978.
106. Hallberg P., Karlsson J., Kurland L., Lind L., Kahan T., Malmqvist K., Ohman K.P., Nystrom F., Melhus H. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J. Hypertens. 2002, 20:2089-2093.
107. Halling J., Petersen M.S., Damkier P., Nielsen F., Grandjean P., Weihe P., Lundgren S., Lundblad M.S., Brosen K. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol. 2005, 61:491-497.
108. Hamdy S.I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M.S., Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 2002, 53:596-603.
109. Hamman M.A., Thompson G.A., Hall S.D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol. 1997, 54:33-41.
110. Hanatani T., Fukuda T., Ikeda M., Imaoka S., Hiroi T., Funae Y., Azuma J. CYP2C9 3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenom. J. 2001, 1:288-292.
111. He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., Woolf T.F. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 2004, 32:639-646.
112. He M., Rettie A.E., Neal J., Trager W.F. Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab. Dispos. 2001, 29:701-711.
113. Helsby N.A., Ward S.A., Howells R.E., Breckenridge A.M. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br. J. Clin. Pharmacol. 1990, 30:287-291.
114. Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9 24) in a patient on warfarin therapy. Thromb. Haemost. 2006, 95:192-194.
115. Hermans J.J., Thijssen H.H. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br. J. Pharmacol. 1993, 110:482-490.
116. Hesse L.M., Venkatakrishnan K., von Moltke L.L., Shader R.I., Greenblatt D.J. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos. 2001, 29:133-140.
117. Hewitt D.J. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin. J. Pain 2000, 16:S73-79.
118. Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 2001, 29:1480-1484.
119. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., Rettie A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
120. Hijazi Y., Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 2002, 30:853-858.
121. Hirani V.N., Raucy J.L., Lasker J.M. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab. Dispos. 2004, 32:1462-1467.
122. Holstein A., Plaschke A., Ptak M., Egberts E.H., El-Din J., Brockmoller J., Kirchheiner J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 2005, 60:103-106.
123. Hong X., Zhang S., Mao G., Jiang S., Zhang Y., Yu Y., Tang G., Xing H., Xu X. CYP2C9 3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur. J. Clin. Pharmacol. 2005, 61:627-634.
124. Howell S.R., Shirley M.A., Grese T.A., Neel D.A., Wells K.E., Ulm E.H. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab. Dispos. 2001, 29:990-998.
125. Hummel M.A., Dickmann L.J., Rettie A.E., Haining R.L., Tracy T.S. Differential activation of CYP2C9 variants by dapsone. Biochem. Pharmacol. 2004, 67:1831-1841.
126. Hummel M.A., Locuson C.W., Gannett P.M., Rock D.A., Mosher C.M., Rettie A.E., Tracy T.S. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol. Pharmacol. 2005, 68:644-651.
127. Hung C.C., Lin C.J., Chen C.C., Chang C.J., Liou H.H. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 2004, 26:534-540.
128. Hyland R., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 2003, 31:540-547.
129. Ieiri I., Tainaka H., Morita T., Hadama A., Mamiya K., Hayashibara M., Ninomiya H., Ohmori S., Kitada M., Tashiro N., Higuchi S., Otsubo K. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 2000, 22:237-244.
130. Iida I., Miyata A., Arai M., Hirota M., Akimoto M., Higuchi S., Kobayashi K., Chiba K. Catalytic roles of CYP2C9 and its variants (CYP2C9 2 and CYP2C9 3) in lornoxicam 5'-hydroxylation. Drug Metab. Dispos. 2004, 32:7-9.
131. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., Yamane M., Fukumaki Y., Ninomiya H., Tashiro N., Otsubo K., Higuchi S. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000, 10:85-89.
132. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116:496-526.
133. Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., Benet L.Z., Christians U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 2000, 28:1369-1378.
134. Jansing R.L., Chao E.S., Kaminsky L.S. Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol. Pharmacol. 1992, 41:209-215.
135. Jetter A., Kinzig-Schippers M., Skott A., Lazar A., Tomalik-Scharte D., Kirchheiner J., Walchner-Bonjean M., Hering U., Jakob V., Rodamer M., Jabrane W., Kasel D., Brockmoller J., Fuhr U., Sorgel F. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur. J. Clin. Pharmacol. 2004, 60:165-171.
136. Jeurissen S.M., Bogaards J.J., Boersma M.G., ter Horst J.P., Awad H.M., Fiamegos Y.C., van Beek T.A., Alink G.M., Sudholter E.J., Cnubben N.H., Rietjens I.M. Human cytochrome P450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol. Chem. Res. Toxicol. 2006, 19:111-116.
137. Jones B.C., Hawksworth G., Horne V.A., Newlands A., Morsman J., Tute M.S., Smith D.A. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab. Dispos. 1996, 24:260-266.
138. Kalgutkar A.S., Nguyen H.T., Vaz A.D., Doan A., Dalvie D.K., McLeod D.G., Murray J.C. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active α-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 2003, 31:1240-1250.
139. Kam P.C., Nethery C.M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003, 58:28-35.
140. Kamali F., Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br. J. Clin. Pharmacol. 2006, 61:746-751.
141. Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73:67-74.
142. Kantola T., Backman J.T., Niemi M., Kivisto K.T., Neuvonen P.J. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 2000, 56:225-229.
143. Karazniewicz-Lada M., Luczak M., Glowka F. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica 2009, 39:476-485.
144. Kariya S., Isozaki S., Uchino K., Suzuki T., Narimatsu S. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol. Pharm. Bull. 1996, 19:1511-1514.
145. Kaukonen K.M., Olkkola K.T., Neuvonen P.J. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 1998, 53:445-449.
146. Kazierad D.J., Martin D.E., Blum R.A., Tenero D.M., Ilson B., Boike S.C., Etheredge R., Jorkasky D.K. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. 1997, 62:417-425.
147. Kharasch E.D., Hankins D.C., Fenstamaker K., Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur. J. Clin. Pharmacol. 2000, 55:853-859.
148. Kidd R.S., Straughn A.B., Meyer M.C., Blaisdell J., Goldstein J.A., Dalton J.T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9 3 allele. Pharmacogenetics 1999, 9:71-80.
149. Kidd R.S., Curry T.B., Gallagher S., Edeki T., Blaisdell J., Goldstein J.A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001, 11:803-808.
150. Kimber-Trojnar Z., Marciniak B., Leszczynska-Gorzelak B., Trojnar M., Oleszczuk J. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol. Rep. 2008, 60:308-318.
151. Kimura M., Ieiri I., Mamiya K., Urae A., Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 1998, 20:243-247.
152. King B.P., Khan T.I., Aithal G.P., Kamali F., Daly A.K. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14:813-822.
153. Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., Roots I., Brockmoller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002, 12:101-109.
154. Kirchheiner J., Brockmoller J., Meineke I., Bauer S., Rohde W., Meisel C., Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 2002, 71:286-296.
155. Kirchheiner J., Meineke I., Freytag G., Meisel C., Roots I., Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther. 2002, 72:62-75.
156. Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I., Brockmoller J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 2003, 74:186-194.
157. Kirchheiner J., Meineke I., Steinbach N., Meisel C., Roots I., Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. 2003, 55:51-61.
158. Kirchheiner J., Stormer E., Meisel C., Steinbach N., Roots I., Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003, 13:473-480.
159. Kirchheiner J., Meineke I., Muller G., Bauer S., Rohde W., Meisel C., Roots I., Brockmoller J. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin. Pharmacokinet. 2004, 43:267-278.
160. Kirchheiner J., Ufer M., Walter E.C., Kammerer B., Kahlich R., Meisel C., Schwab M., Gleiter C.H., Rane A., Roots I., Brockmoller J. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004, 14:19-26.
161. Knauf H., Spahn H., Mutschler E. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. Drugs 1991, 41(Suppl. 3):23-34.
162. Knauf H., Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet. 1998, 34:1-24.
163. Knodell R.G., Dubey R.K., Wilkinson G.R., Guengerich F.P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J. Pharmacol. Exp. Ther. 1988, 245:845-849.
164. Ko J.W., Desta Z., Flockhart D.A. Human N-demethylation of S-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos. 1998, 26:775-778.
165. Kobayashi K., Ishizuka T., Shimada N., Yoshimura Y., Kamijima K., Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P450 in vitro. Drug Metab. Dispos. 1999, 27:763-766.
166. Kobayashi K., Nakajima M., Oshima K., Shimada N., Yokoi T., Chiba K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab. Dispos. 1999, 27:860-865.
167. Komori M., Hashizume T., Ohi H., Miura T., Kitada M., Nagashima K., Kamataki T. Cytochrome P450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. J. Biochem. 1988, 104:912-916.
168. Kot M., Daniel W.A. The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem. Pharmacol. 2008, 76:543-551.
169. Kramer M.A., Rettie A.E., Rieder M.J., Cabacungan E.T., Hines R.N. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol. Pharmacol. 2008, 73:1751-1760.
170. Kumar G.N., Dubberke E., Rodrigues A.D., Roberts E., Dennisen J.F. Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab. Dispos. 1997, 25:110-115.
171. Kumar V., Wahlstrom J.L., Rock D.A., Warren C.J., Gorman L.A., Tracy T.S. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab. Dispos. 2006, 34:1966-1975.
172. Kurata N., Nishimura Y., Iwase M., Fischer N.E., Tang B.K., Inaba T., Yasuhara H. Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica 1998, 28:1041-1047.
173. Lai W.G., Zahid N., Uetrecht J.P. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther. 1999, 291:292-299.
174. Laine J.E., Auriola S., Pasanen M., Juvonen R.O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009, 39:11-21.
175. Lal S., Jada S.R., Xiang X., Lim W.T., Lee E.J., Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin. Pharmacokinet. 2006, 45:1189-1200.
176. Langer O. Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. Obstet. Gynecol. Clin. North Am. 2007, 34:255-274. ix.
177. Lasker J.M., Wester M.R., Aramsombatdee E., Raucy J.L. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys. 1998, 353:16-28.
178. Lee A.Y., Kim M.J., Chey W.Y., Choi J., Kim B.G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol. 2004, 60:155-159.
179. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12:251-263.
180. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Differences in flurbiprofen pharmacokinetics between CYP2C9 1/ 1, 1/ 2, and 1/ 3 genotypes. Eur. J. Clin. Pharmacol. 2003, 58:791-794.
181. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 2003, 43:84-91.
182. Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9 1/ 1, 1/ 2, and 1/ 3 individuals. Pharmacotherapy 2003, 23:720-725.
183. Leemann T., Kondo M., Zhao J., Transon C., Bonnabry P., Dayer P. [The biotransformation of NSAIDs: a common elimination site and drug interactions]. Schweiz Med. Wochenschr. 1992, 122:1897-1899.
184. Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci. 1993, 52:29-34.
185. Li Y., Slatter J.G., Zhang Z., Li Y., Doss G.A., Braun M.P., Stearns R.A., Dean D.C., Baillie T.A., Tang W. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos. 2008, 36:469-473.
186. Lima M.V., Ribeiro G.S., Mesquita E.T., Victer P.R., Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur. J. Clin. Pharmacol. 2008, 64:9-15.
187. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 1998, 35:361-390.
188. Liu Y.L., Zhang W., Tan Z.R., Ouyang D.S., Luo C.H., Liu Z.Q., Qiu Y., Chen Y., He Y.J., Zhou G., Zhou H.H. Effect of the CYP2C9 3 allele on lornoxicam metabolism. Clin. Chim. Acta 2006, 364:287-291.
189. Llerena A., Berecz R., Dorado P., Gonzalez A.P., Penas L.E.M., De La Rubia A. CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenom. J. 2003, 3:300-302.
190. Llerena A., Dorado P., Berecz R., Gonzalez A.P., Penas L.E.M. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur. J. Clin. Pharmacol. 2004, 59:869-873.
191. Llerena A., Dorado P., O'Kirwan F., Jepson R., Licinio J., Wong M.L. Lower frequency of CYP2C9 2 in Mexican-Americans compared to Spaniards. Pharmacogenom. J. 2004, 4:403-406.
192. Lo M.W., Goldberg M.R., McCrea J.B., Lu H., Furtek C.I., Bjornsson T.D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 1995, 58:641-649.
193. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., Roitelman J., Harats D., Halkin H., Ezra D. Interindividual variability in sensitivity to warfarin-Nature or nurture?. Clin. Pharmacol. Ther. 2001, 70:159-164.
194. London S.J., Daly A.K., Leathart J.B.S., Navidi W.C., Idle J.R. Lung cancer risk in relation to the CYP2C9 1/CYP2C9 2 genetic polymorphism among African-Americans and Caucasians in Los Angeles county, California. Pharmacogenetics 1996, 6:527-533.
195. Lu J., Helsby N., Palmer B.D., Tingle M., Baguley B.C., Kestell P., Ching L.M. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J. Pharmacol. Exp. Ther. 2004, 310:571-577.
196. Lundblad M.S., Ohlsson S., Johansson P., Lafolie P., Eliasson E. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9 3. Clin. Pharmacol. Ther. 2006, 79:287-288.
197. Machinist J.M., Mayer M.D., Shet M.S., Ferrero J.L., Rodrigues A.D. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab. Dispos. 1995, 23:1163-1174.
198. Machinist J.M., Mayer M.D., Roberts E.M., Surber B.W., Rodrigues A.D. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab. Dispos. 1998, 26:970-976.
199. Maekawa K., Fukushima-Uesaka H., Tohkin M., Hasegawa R., Kajio H., Kuzuya N., Yasuda K., Kawamoto M., Kamatani N., Suzuki K., Yanagawa T., Saito Y., Sawada J. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genom. 2006, 16:497-514.
200. Maguire J.H. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsia 1988, 29:753-759.
201. Mamiya K., Ieiri I., Shimamoto J., Yukawa E., Imai J., Ninomiya H., Yamada H., Otsubo K., Higuchi S., Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998, 39:1317-1323.
202. Mancy A., Broto P., Dijols S., Dansette P.M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995, 34:10365-10375.
203. Mancy A., Dijols S., Poli S., Guengerich P., Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry 1996, 35:16205-16212.
204. Margolis J.M., O'Donnell J.P., Mankowski D.C., Ekins S., Obach R.S. R-, S-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000, 28:1187-1191.
205. Marill J., Cresteil T., Lanotte M., Chabot G.G. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol. 2000, 58:1341-1348.
206. Marino M.R., Langenbacher K., Ford N.F., Uderman H.D. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J. Clin. Pharmacol. 1998, 38:246-255.
207. Marino M.R., Vachharajani N.N. Pharmacokinetics of irbesartan are not altered in special populations. J. Cardiovasc. Pharmacol. 2002, 40:112-122.
208. Martens-Lobenhoffer J., Banditt P. Clinical pharmacokinetics of dorzolamide. Clin. Pharmacokinet. 2002, 41:197-205.
209. Martin J.H., Begg E.J., Kennedy M.A., Roberts R., Barclay M.L. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. Br. J. Clin. Pharmacol. 2001, 51:627-630.
210. Martin P.D., Warwick M.J., Dane A.L., Hill S.J., Giles P.B., Phillips P.J., Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 2003, 25:2822-2835.
211. Martinez C., Blanco G., Ladero J.M., Garcia-Martin E., Taxonera C., Gamito F.G., Diaz-Rubio M., Agundez J.A. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 2004, 141:205-208.
212. Martinez C., Garcia-Martin E., Blanco G., Gamito F.J., Ladero J.M., Agundez J.A. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol. 2005, 59:62-69.
213. Mas S., Crescenti A., Vidal-Taboada J.M., Bergonon S., Cuevillas F., Laso N., Molina R., Ballesta A., Lafuente A. Simultaneous genotyping of CYP2C9 2, 3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur. J. Clin. Pharmacol. 2005, 61:635-641.
214. Matimba A., Del-Favero J., Van Broeckhoven C., Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum. Genom. 2009, 3:169-190.
215. Mayersohn M., Guentert T.W. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin. Pharmacokinet. 1995, 29:292-332.
216. McLeod J.F. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin. Pharmacokinet. 2004, 43:97-120.
217. Meadowcroft A.M., Williamson K.M., Patterson J.H., Hinderliter A.L., Pieper J.A. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 1999, 39:418-424.
218. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W.L., Braunwald E., Sabatine M.S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
219. Mellstrom B., von Bahr C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab. Dispos. 1981, 9:565-568.
220. Miao L., Yang J., Huang C., Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol. 2007, 63:1135-1141.
221. Miller J.L., Trepanier L.A. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Eur. J. Clin. Pharmacol. 2002, 58:69-72.
222. Miners J.O., Smith K.J., Robson R.A., McManus M.E., Veronese M.E., Birkett D.J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 1988, 37:1137-1144.
223. Miners J.O., Rees D.L., Valente L., Veronese M.E., Birkett D.J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995, 272:1076-1081.
224. Miners J.O., Birkett D.J. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998, 45:525-538.
225. Miyazawa M., Shindo M., Shimada T. Sex differences in the metabolism of (+)- and (-)-limonene enantiomers to carveol and perillyl alcohol derivatives by cytochrome P450 enzymes in rat liver microsomes. Chem. Res. Toxicol. 2002, 15:15-20.
226. Mizuno C.S., Chittiboyina A.G., Kurtz T.W., Pershadsingh H.A., Avery M.A. Type 2 diabetes and oral antihyperglycemic drugs. Curr. Med. Chem. 2008, 15:61-74.
227. Momary K.M., Shapiro N.L., Viana M.A., Nutescu E.A., Helgason C.M., Cavallari L.H. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007, 8:1535-1544.
228. Monostory K., Pascussi J.M., Szabo P., Temesvari M., Kohalmy K., Acimovic J., Kocjan D., Kuzman D., Wilzewski B., Bernhardt R., Kobori L., Rozman D. Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent. Drug Metab. Dispos. 2009, 37:375-385.
229. Nakajima M., Inoue T., Shimada N., Tokudome S., Yamamoto T., Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab. Dispos. 1998, 26:261-266.
230. Nakajima M., Nakamura S., Tokudome S., Shimada N., Yamazaki H., Yokoi T. Azelastine N-demethylation by CYP3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab. Dispos. 1999, 27:1381-1391.
231. Nakamura M., Tanaka E., Misawa S., Shimada T., Imaoka S., Funae Y. Trimethadione metabolism, a useful indicator for assessing hepatic drug-oxidizing capacity. Biochem. Pharmacol. 1994, 47:247-251.
232. Nakashima A., Kawashita H., Masuda N., Saxer C., Niina M., Nagae Y., Iwasaki K. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica 2005, 35:589-602.
233. Naritomi Y., Terashita S., Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004, 34:415-427.
234. Nasu K., Kubota T., Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997, 7:405-409.
235. Neugebauer G., Besenfelder E., von Mollendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung 1988, 38:164-166.
236. Ngow H., Teh L.K., Langmia I.M., Lee W.L., Harun R., Ismail R., Salleh M.Z. Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study. Xenobiotica 2008, 38:641-651.
237. Niemi M., Cascorbi I., Timm R., Kroemer H.K., Neuvonen P.J., Kivisto K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 2002, 72:326-332.
238. O'Donnell J.P., Dalvie D.K., Kalgutkar A.S., Obach R.S. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab. Dispos. 2003, 31:1369-1377.
239. O'Reilly R.A. Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther. 1974, 16:348-354.
240. Odani A., Hashimoto Y., Otsuki Y., Uwai Y., Hattori H., Furusho K., Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 1997, 62:287-292.
241. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos. 2000, 28:1303-1310.
242. Oldham H.G., Clarke S.E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 1997, 25:970-977.
243. Olesen O.V., Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br. J. Clin. Pharmacol. 2000, 50:563-571.
244. Oliveira E., Marsh S., van Booven D.J., Amorim A., Prata M.J., McLeod H.L. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007, 8:703-712.
245. Oner Ozgon G., Langaee T.Y., Feng H., Buyru N., Ulutin T., Hatemi A.C., Siva A., Saip S., Johnson J.A. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur. J. Clin. Pharmacol. 2008, 64:889-894.
246. Ono S., Hatanaka T., Miyazawa S., Tsutsui M., Aoyama T., Gonzalez F.J., Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996, 26:1155-1166.
247. Otake Y., Walle T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab. Dispos. 2002, 30:103-105.
248. Pan L.P., De Vriendt C., Belpaire F.M. In vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998, 8:383-389.
249. 14C-celecoxib in healthy male volunteers. Drug Metab. Dispos. 2000, 28:308-314.
250. Pearce R., Greenway D., Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 1992, 298:211-225.
251. Pearce R.E., Rodrigues A.D., Goldstein J.A., Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 1996, 277:805-816.
252. Pekol T., Daniels J.S., Labutti J., Parsons I., Nix D., Baronas E., Hsieh F., Gan L.S., Miwa G. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab. Dispos. 2005, 33:771-777.
253. Perini J.A., Vianna-Jorge R., Brogliato A.R., Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 2005, 78:362-369.
254. 1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J. Pharmacol. Exp. Ther. 1994, 271:91-99.
255. Peyvandi F., Spreafico M., Karimi M., Zeinali S., Mannucci P.M., Bianchi Bonomi A. Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb. Haemost. 2002, 88:874-875.
256. Picard N., Cresteil T., Djebli N., Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 2005, 33:689-695.
257. Pichard L., Gillet G., Bonfils C., Domergue J., Thenot J.P., Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab. Dispos. 1995, 23:1253-1262.
258. Pilotto A., Seripa D., Franceschi M., Scarcelli C., Colaizzo D., Grandone E., Niro V., Andriulli A., Leandro G., Di Mario F., Dallapiccola B. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007, 133:465-471.
259. Poli-Scaife S., Attias R., Dansette P.M., Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 1997, 36:12672-12682.
260. Preiss R., Schmidt R., Baumann F., Hanschmann H., Hauss J., Geissler F., Pahlig H., Ratzewiss B. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J. Cancer. Res. Clin. Oncol. 2002, 128:385-392.
261. Prueksaritanont T., Gorham L.M., Ma B., Liu L., Yu X., Zhao J.J., Slaughter D.E., Arison B.H., Vyas K.P. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 1997, 25:1191-1199.
262. Prueksaritanont T., Ma B., Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 2003, 56:120-124.
263. Ravindran S., Zharikova O.L., Hill R.A., Nanovskaya T.N., Hankins G.D., Ahmed M.S. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem. Pharmacol. 2006, 72:1730-1737.
264. Rehmel J.L., Eckstein J.A., Farid N.A., Heim J.B., Kasper S.C., Kurihara A., Wrighton S.A., Ring B.J. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos. 2006, 34:600-607.
265. 14C]omeprazole in humans. Drug Metab. Dispos. 1989, 17:69-76.
266. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 2002, 34:83-448.
267. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4:39-42.
268. Rettie A.E., Jones J.P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 2005, 45:477-494.
269. Rifkind A.B., Lee C., Chang T.K., Waxman D.J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys. 1995, 320:380-389.
270. 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 1996, 24:126-136.
271. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug Metab. Dispos. 2005, 33:1567-1575.
272. Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily. Biochemistry 1991, 30:3247-3255.
273. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G., Muller C.R., Strom T.M., Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature 2004, 427:537-541.
274. Rydberg T., Jonsson A., Roder M., Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diab. Care 1994, 17:1026-1030.
275. Rydberg T., Jonsson A., Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J. Clin. Pharm. Ther. 1995, 20:283-295.
276. Sadeque A.J., Fisher M.B., Korzekwa K.R., Gonzalez F.J., Rettie A.E. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 1997, 283:698-703.
277. Sandberg M., Yasar U., Stromberg P., Hoog J.O., Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br. J. Clin. Pharmacol. 2002, 54:423-429.
278. Sandwall P., Lo M.W., Jonzon B., Dalen P., Furtek C., Ritter M., Alvan G., McCrea J., Sjoqvist F. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Eur. J. Clin. Pharmacol. 1999, 55:279-283.
279. 3 antagonists. Drug Metab. Dispos. 1996, 24:602-609.
280. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost. 2005, 31:174-183.
281. Savidge R.D., Bui K.H., Birmingham B.K., Morse J.L., Spreen R.C. Metabolism and excretion of zafirlukast in dogs, rats, and mice. Drug Metab. Dispos. 1998, 26:1069-1076.
282. Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Vena R., Friedman H.L., Shader R.I. Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P450 2C9 and metabolic inhibitors. J. Clin. Pharmacol. 1997, 37:193-200.
283. Scordo M.G., Aklillu E., Yasar U., Dahl M.L., Spina E., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 2001, 52:447-450.
284. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 2002, 72:702-710.
285. Scripture C.D., Pieper J.A. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 2001, 40:263-281.
286. Sekino K., Kubota T., Okada Y., Yamada Y., Yamamoto K., Horiuchi R., Kimura K., Iga T. Effect of the single CYP2C9 3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur. J. Clin. Pharmacol. 2003, 59:589-592.
287. Shen S., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 1999, 12:214-222.
288. Shimamoto J., Ieiri I., Urae A., Kimura M., Irie S., Kubota T., Chiba K., Ishizaki T., Otsubo K., Higuchi S. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9 3 allele. Eur. J. Clin. Pharmacol. 2000, 56:65-68.
289. Shintani M., Ieiri I., Inoue K., Mamiya K., Ninomiya H., Tashiro N., Higuchi S., Otsubo K. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin. Pharmacol. Ther. 2001, 70:175-182.
290. Shon J.H., Yoon Y.R., Kim K.A., Lim Y.C., Lee K.J., Park J.Y., Cha I.J., Flockhart D.A., Shin J.G. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002, 12:111-119.
291. Shon J.H., Yoon Y.R., Kim M.J., Kim K.A., Lim Y.C., Liu K.H., Shin D.H., Lee C.H., Cha I.J., Shin J.G. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br. J. Clin. Pharmacol. 2005, 59:552-563.
292. Si D., Guo Y., Zhang Y., Yang L., Zhou H., Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004, 14:465-469.
293. Slaughter D., Takenaga N., Lu P., Assang C., Walsh D.J., Arison B.H., Cui D., Halpin R.A., Geer L.A., Vyas K.P., Baillie T.A. Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab. Dispos. 2003, 31:1398-1408.
294. Soga Y., Nishimura F., Ohtsuka Y., Araki H., Iwamoto Y., Naruishi H., Shiomi N., Kobayashi Y., Takashiba S., Shimizu K., Gomita Y., Oka E. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 2004, 74:827-834.
295. Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q., McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P. Genetic variation in eleven Phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004, 5:895-931.
296. Srivastava P.K., Yun C.H., Beaune P.H., Ged C., Guengerich F.P. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P450 enzymes. Mol. Pharmacol. 1991, 40:69-79.
297. Stearns R.A., Miller R.R., Doss G.A., Chakravarty P.K., Rosegay A., Gatto G.J., Chiu S.H. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab. Dispos. 1992, 20:281-287.
298. Stearns R.A., Chakravarty P.K., Chen R., Chiu S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 1995, 23:207-215.
299. Stempak D., Bukaveckas B.L., Linder M., Koren G., Baruchel S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin. Pharmacol. Ther. 2005, 78:309-310.
300. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
301. 2-oxide. Cancer Res. 2004, 64:8374-8380.
302. Stormer E., Brockmoller J., Roots I., Schmider J. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl.) 2000, 151:312-320.
303. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996, 6:429-439.
304. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6:341-349.
305. Sundstrom I., Bondesson U., Hedeland M. Identification of Phase I and Phase II metabolites of ketobemidone in patient urine using liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2001, 763:121-131.
306. Sundstrom I., Hedeland M., Bondesson U., Andren P.E. Identification of glucuronide conjugates of ketobemidone and its phase I metabolites in human urine utilizing accurate mass and tandem time-of-flight mass spectrometry. J. Mass Spectrom. 2002, 37:414-420.
307. Sutton D., Butler A.M., Nadin L., Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharmacol. Exp. Ther. 1997, 282:294-300.
308. Suzuki K., Yanagawa T., Shibasaki T., Kaniwa N., Hasegawa R., Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diab. Res. Clin. Pract. 2006, 72:148-154.
309. Swinney D.C. Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P450 inhibitor, ketoconazole, and the NADPH 5 α-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat. Drug Metab. Dispos. 1990, 18:859-865.
310. Taavitsainen P., Anttila M., Nyman L., Karnani H., Salonen J.S., Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol. Toxicol. 2000, 86:215-221.
311. Taguchi K., Konishi T., Nishikawa H., Kitamura S. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid. Xenobiotica 1999, 29:899-907.
312. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001, 40:587-603.
313. Takanashi K., Tainaka H., Kobayashi K., Yasumori T., Hosakawa M., Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000, 10:95-104.
314. Tanaka E., Kurata N., Yasuhara H. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J. Clin. Pharm. Ther. 2003, 28:493-496.
315. Tang C., Shou M., Mei Q., Rushmore T.H., Rodrigues A.D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 2000, 293:453-459.
316. Tang C., Shou M., Rushmore T.H., Mei Q., Sandhu P., Woolf E.J., Rose M.J., Gelmann A., Greenberg H.E., De Lepeleire I., Van Hecken A., De Schepper P.J., Ebel D.L., Schwartz J.I., Rodrigues A.D. In vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics. Pharmacogenetics 2001, 11:223-235.
317. Tang W., Stearns R.A., Wang R.W., Chiu S.H., Baillie T.A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 1999, 12:192-199.
318. Tanira M.O., Al-Mukhaini M.K., Al-Hinai A.T., Al Balushi K.A., Ahmed I.S. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Commun. Genet. 2007, 10:32-37.
319. Taube J., Halsall D., Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000, 96:1816-1819.
320. Thijssen H.H., Flinois J.P., Beaune P.H. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. 2000, 28:1284-1290.
321. Thijssen H.H., Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. Ther. 2003, 74:61-68.
322. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993, 45:205-251.
323. 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol. 1998, 46(Suppl 1):19-24.
324. Tougou K., Gotou H., Ohno Y., Nakamura A. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica 2004, 34:449-461.
325. Tracy T.S., Rosenbluth B.W., Wrighton S.A., Gonzalez F.J., Korzekwa K.R. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of R- and S-flurbiprofen. Biochem. Pharmacol. 1995, 49:1269-1275.
326. Tracy T.S., Hutzler J.M., Haining R.L., Rettie A.E., Hummel M.A., Dickmann L.J. Polymorphic variants (CYP2C9 3 and CYP2C9 5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 2002, 30:385-390.
327. Transon C., Leemann T., Vogt N., Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. 1995, 58:412-417.
328. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 1996, 50:209-215.
329. Treluyer J.M., Bowers G., Cazali N., Sonnier M., Rey E., Pons G., Cresteil T. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab. Dispos. 2003, 31:275-281.
330. Tsuda-Tsukimoto M., Ogasawara Y., Kume T. Role of human liver cytochrome P450 2C9 in the metabolism of a novel α4β1/α4β7 dual antagonist, TR-14035. Drug Metab. Pharmacokinet. 2005, 20:127-134.
331. Tugnait M., Hawes E.M., McKay G., Eichelbaum M., Midha K.K. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem. Biol. Interact. 1999, 118:171-189.
332. Tuvesson H., Gunnarsson P.O., Seidegard J. Metabolism of tauromustine in liver and lung microsomes from various species. Xenobiotica 1999, 29:783-792.
333. Uchida S., Watanabe H., Nishio S., Hashimoto H., Yamazaki K., Hayashi H., Ohashi K. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin. Pharmacol. Ther. 2003, 74:505-508.
334. Uehleke H., Tabarelli S. N-Hydroxylation of 4,4-diaminodiphenyl-sulfone (dapsone) by liver microsomes and in dogs and humans. Naunyn-Schmeideberg's Arch. Pharmacol. 1973, 278:55-68.
335. Ufer M., Kammerer B., Kahlich R., Kirchheiner J., Yasar U., Brockmoller J., Rane A. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004, 34:847-859.
336. Ufer M., Svensson J.O., Krausz K.W., Gelboin H.V., Rane A., Tybring G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur. J. Clin. Pharmacol. 2004, 60:173-182.
337. Vachharajani N.N., Yeleswaram K., Boulton D.W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J. Pharm. Sci. 2003, 92:760-772.
338. van der Weide J., Steijns L.S., van Weelden M.J., de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001, 11:287-291.
339. Veenstra D.L., Blough D.K., Higashi M.K., Farin F.M., Srinouanprachan S., Rieder M.J., Rettie A.E. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 2005, 77:353-364.
340. Venkatakrishnan K., von Moltke L.L., Duan S.X., Fleishaker J.C., Shader R.I., Greenblatt D.J. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J. Pharm. Pharmacol. 1998, 50:265-274.
341. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J. Pharm. Sci. 1998, 87:845-853.
342. Vermeir M., Hemeryck A., Cuyckens F., Francesch A., Bockx M., Van Houdt J., Steemans K., Mannens G., Aviles P., De Coster R. In vitro studies on the metabolism of trabectedin (Yondelis) in monkey and man, including human CYP reaction phenotyping. Biochem. Pharmacol. 2009, 77:1642-1654.
343. Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., Birkett D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 1991, 175:1112-1118.
344. Vianna-Jorge R., Perini J.A., Rondinelli E., Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 2004, 76:18-26.
345. Vickers A.E., Sinclair J.R., Zollinger M., Heitz F., Glanzel U., Johanson L., Fischer V. Multiple cytochrome P450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 1999, 27:1029-1038.
346. Vickers S., Duncan C.A., Vyas K.P., Kari P.H., Arison B., Prakash S.R., Ramjit H.G., Pitzenberger S.M., Stokker G., Duggan D.E. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 1990, 18:476-483.
347. von Moltke L.L., Greenblatt D.J., Giancarlo G.M., Granda B.W., Harmatz J.S., Shader R.I. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 2001, 29:1102-1109.
348. Vormfelde S.V., Engelhardt S., Zirk A., Meineke I., Tuchen F., Kirchheiner J., Brockmoller J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 2004, 76:557-566.
349. Wadelius M., Sorlin K., Wallerman O., Karlsson J., Yue Q.Y., Magnusson P.K., Wadelius C., Melhus H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenom. J. 2004, 4:40-48.
350. Wang B., Sanchez R.I., Franklin R.B., Evans D.C., Huskey S.E. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethinylestradiol. Drug Metab. Dispos. 2004, 32:1209-1212.
351. Wang J.S., Backman J.T., Taavitsainen P., Neuvonen P.J., Kivisto K.T. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab. Dispos. 2000, 28:959-965.
352. Wang R., Chen K., Wen S.Y., Li J., Wang S.Q. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther. 2005, 78:90-92.
353. Wang R.W., Kari P.H., Lu A.Y., Thomas P.E., Guengerich F.P., Vyas K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 1991, 290:355-361.
354. Wang S.L., Huang J., Lai M.D., Tsai J.J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995, 5:37-42.
355. Warrington J.S., Shader R.I., von Moltke L.L., Greenblatt D.J. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. 2000, 28:392-397.
356. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007, 80:1415-1419.
357. Weaver R.J., Dickins M., Burke M.D. Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations. Biochem. Pharmacol. 1995, 49:997-1004.
358. Wei L., Locuson C.W., Tracy T.S. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol. Pharmacol. 2007, 72:1280-1288.
359. Wen S.Y., Wang H., Sun O.J., Wang S.Q. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J. Gastroenterol. 2003, 9:1342-1346.
360. Werner U., Werner D., Pahl A., Mundkowski R., Gillich M., Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed. Chromatogr. 2002, 16:56-60.
361. Wester M.R., Lasker J.M., Johnson E.F., Raucy J.L. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab. Dispos. 2000, 28:354-359.
362. Wester M.R., Yano J.K., Schoch G.A., Yang C., Griffin K.J., Stout C.D., Johnson E.F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J. Biol. Chem. 2004, 279:35630-35637.
363. Williams P.A., Cosme J., Ward A., Angove H.C., Matak Vinkovic D., Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424:464-468.
364. Winter H.R., Wang Y., Unadkat J.D. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab. Dispos. 2000, 28:865-868.
365. Winter H.R., Unadkat J.D. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab. Dispos. 2005, 33:969-976.
366. Wojcikowski J., Pichard-Garcia L., Maurel P., Daniel W.A. Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br. J. Pharmacol. 2003, 138:1465-1474.
367. Wojcikowski J., Pichard-Garcia L., Maurel P., Daniel W.A. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur. Neuropsychopharmacol. 2004, 14:199-208.
368. Wynne H.A., Long A., Nicholson E., Ward A., Keir D. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?. Br. J. Clin. Pharmacol. 1998, 45:405-408.
369. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 2002, 54:1257-1270.
370. Yamazaki H., Inoue K., Shaw P.M., Checovich W.J., Guengerich F.P., Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J. Pharmacol. Exp. Ther. 1997, 283:434-442.
371. Yamazaki H., Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 1997, 346:161-169.
372. Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., Goldstein J.A., Guengerich F.P., Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 1998, 56:243-251.
373. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metab. Dispos. 1999, 27:1260-1266.
374. Yasar U., Eliasson E., Dahl M.L., Johansson I., Ingelman-Sundberg M., Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 1999, 254:628-631.
375. Yasar U., Eliasson E., Forslund-Bergengren C., Tybring G., Gadd M., Sjoqvist F., Dahl M.L. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. 2001, 57:729-735.
376. Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M.L., Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 2001, 29:1051-1056.
377. Yasar U., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjoqvist F., Eliasson E., Dahl M.L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 2002, 71:89-98.
378. Yasar U., Lundgren S., Eliasson E., Bennet A., Wiman B., de Faire U., Rane A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 2002, 299:25-28.
379. Yasar U., Annas A., Svensson J.O., Lazorova L., Artursson P., Al-Shurbaji A. Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica 2005, 35:785-796.
380. Yasumori T., Nagata K., Yang S.K., Chen L.S., Murayama N., Yamazoe Y., Kato R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993, 3:291-301.
381. Yin O.Q., Tomlinson B., Chow M.S. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther. 2005, 78:370-377.
382. Yin T., Maekawa K., Kamide K., Saito Y., Hanada H., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., Otsuki T., Horio T., Takiuchi S., Kawano Y., Minematsu K., Naritomi H., Tomoike H., Sawada J., Miyata T. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res. 2008, 31:1549-1557.
383. Yoon Y.R., Shon J.H., Kim M.K., Lim Y.C., Lee H.R., Park J.Y., Cha I.J., Shin J.G. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 2001, 51:277-280.
384. Yun C.H., Lee H.S., Lee H., Rho J.K., Jeong H.G., Guengerich F.P. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. 1995, 23:285-289.
385. Zand N., Tajik N., Moghaddam A.S., Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin. Exp. Pharmacol. Physiol. 2007, 34:102-105.
386. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:23-37.
387. Zgheib N.K., Frye R.F., Tracy T.S., Romkes M., Branch R.A. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin. Pharmacol. Ther. 2006, 80:257-263.
388. Zhang Y., Zhong D., Si D., Guo Y., Chen X., Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol. 2005, 59:14-17.
389. Zhao F., Loke C., Rankin S.C., Guo J.Y., Lee H.S., Wu T.S., Tan T., Liu T.C., Lu W.L., Lim Y.T., Zhang Q., Goh B.C., Lee S.C. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 2004, 76:210-219.
390. Zharikova O.L., Ravindran S., Nanovskaya T.N., Hill R.A., Hankins G.D., Ahmed M.S. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem. Pharmacol. 2007, 73:2012-2019.
391. Zhou S.F., Di Y.M., Chan E., Du Y.M., Chow V.D., Xue C.C., Lai X., Wang J.C., Li C.G., Tian M., Duan W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 2008, 9:738-784.
392. Zhou S.F., Liu J.P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 2009, 41:89-295.
393. Zhou S.F., Zhou Z.W., Yang L.P., Cai J.P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem. 2009, 16:3480-3675.